An EMCDDA Paper released today provides an overview of the information available on drug-related homicide (DRH) in Europe. This first snapshot provides practitioners and policymakers with the current state of the art on this topic.
25.05.2018
Čtěte více
Čtěte více
EMCDDA Director Alexis Goosdeel will today address the 38th Congress of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT) taking place on 23 and 24 May in Bucharest. A key theme on the congress programme is the emergence of new psychoactive substances (NPS). 24.05.2018
Čtěte více
What are the most (cost-) effective ways to prevent and control communicable diseases in prison settings? In their joint public health Guidance, ECDC and the EMCDDA present evidence on active case finding as a key measure to diagnose communicable diseases early. The publication is launched in the first Spring European Hepatitis-HIV Testing Week (18–25 May 2018).
23.05.2018
Čtěte více
Čtěte více
Čtěte více
Frequently asked questions on cannabis use and road safety 23.05.2018
What is the impact of cannabis use on driving? Do edible and smoked cannabis products affect drivers in the same way? These are among the questions addressed in a new policy briefing on cannabis and driving, published today.
Čtěte více
EMCDDA Director Alexis Goosdeel will address a conference hosted by the Lithuanian Drug, Tobacco and Alcohol Control Department (NTAKD) in Vilnius today, as the organisation prepares to present a new strategy (2018–2028) to the Lithuanian parliament and government.
Dedicated to Lithuania’s drug policy review, with its human rights and health approach, the conference will underline the importance of a balanced and long-term drug policy, geared towards the creation of a healthy and safe society. 15.05.2018
Čtěte více
Čtěte více
Čtěte více
Council implementing decision to control ADB-CHMINACA and CUMYL-4CN-BINACA 14.05.2018
Today the European Union has decided to subject two new synthetic cannabinoids to control measures across the 28 Member States. The substances in question are ADB-CHMINACA and CUMYL-4CN-BINACA, which have been raising health concerns in Europe.
Čtěte více
